立场声明:欧盟需立法要求医疗器械披露并标示成分
该立场声明指出,医疗器械相关过敏性接触皮炎等皮肤反应日益增多,被视为发展中的流行病。由于医疗器械成分缺乏标示且制造商常不配合披露信息,患者诊疗受到显著影响。文章呼吁在欧盟医疗器械法规实施中强制要求完整成分标示。
要点
- 医疗器械相关过敏性接触皮炎等皮肤反应日益增多,被视为发展中的流行病。
- 成分缺乏标示及制造商不配合披露信息,显著妨碍患者诊疗。
- 呼吁欧盟立法强制要求与人体接触的医疗器械完整准确标示化学成分。
核心结论
- 亟需对与人体接触的医疗器械化学成分进行完整准确标示。
研究设计与样本
- 立场声明,回顾科学文献与现行医疗器械监管框架,并评估无成分标示的潜在影响及部分成本数据。
主要发现
- 科学团队通过寻求企业合作或对医疗器械进行昂贵化学分析来识别不良反应元凶,仅能部分且显著延迟地弥补成分信息缺失。
- 缺乏化学成分信息时,医生无法告知患者应避免哪些物质及哪些替代医疗器械可能适用或耐受。
临床怎么用
- 临床医生在怀疑医疗器械相关皮肤反应时,因成分信息缺失难以指导患者避免致敏物质及选择替代产品。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In recent years, skin reactions secondary to the use of medical devices (MD), such as allergic contact dermatitis have increasingly been observed (e.g. to continuous blood sugar monitoring systems, insulin pumps, wound dressings, medical gloves, etc.): this is regarded as a developing epidemic. Lack of labelling of the composition of MD, as well as frequent lack of cooperation of manufacturers to disclose this relevant information, even when contacted by the clinician for the individual case of an established adverse reaction, significantly impede patient care. OBJECTIVES: To advocate for full ingredient labelling in the implementation of EU regulation for MD. METHODS: This position paper reviews the scientific literature, the current regulatory framework adopted for MD to date, and the likely impact, including some costs data in case of the absence of such labelling. RESULTS: Efforts made by several scientific teams, who are trying to identify the culprit of such adverse effects, either via asking for cooperation from companies, or using costly chemical analyses of MD, can only partly, and with considerable delay, compensate for the absence of meaningful information on the composition of MD; hence, patient management is compromised. Indeed, without knowing the chemical substances present, physicians are unable to inform patients about which substances they should avoid, and which alternative MD may be suitable/tolerated. CONCLUSION: There is an urgent need for full and accurate labelling of the chemical composition of MD in contact with the human body.
引用
- Herman A, Uter W, Rustemeyer T, et al. Position statement: The need for EU legislation to require disclosure and labelling of the composition of medical devices. J Eur Acad Dermatol Venereol. 2021. PMID: 33955077. doi:10.1111/jdv.17238
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。